Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 1/2 2

Status

Terminated 2Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 3Tumor-Agnostic 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Colorectal Neoplasms 6Neoplasms 4Neoplasm Metastasis 4Colonic Neoplasms 4Pancreatic Neoplasms 3Lung Neoplasms 2Carcinoma, Renal Cell 2Advanced Solid Tumor 2Kidney Neoplasms 1Healthy Adults 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × adagrasib × Clear all
NCT06764771 2025-12-17

A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

Bristol-Myers Squibb

Phase 1 Active not recruiting
437 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Neoplasms, Colorectal Neoplasms

NCT05840510 2025-04-25

Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)

Mirati Therapeutics Inc.

Phase 1 Terminated
6 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT04330664 2025-04-04

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

Mirati Therapeutics Inc.

Phase 1 Completed
86 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04975256 2024-12-16

Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)

Mirati Therapeutics Inc.

Phase 1 Terminated
7 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡